Company news
Neovasc Inc news in 2019
Neovasc Inc's news releases, calls and decks from 2019, newest first.
Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer(TM)
December 31, 2019
Neovasc Reducer(TM) Featured In National Geographic Magazine
December 17, 2019
Neovasc Named Finalist in Questex's Fierce Innovation Awards Lifesciences Edition 2019
December 4, 2019
Neovasc Reducer(TM) Featured In FOCUS Magazine
November 26, 2019
Neovasc Reducer(TM) Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola
November 22, 2019
Neovasc Tiara(TM) Progress Highlighted at PCR London Valves 2019
November 19, 2019
Neovasc Reducer(TM) Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany
November 12, 2019
Neovasc Announces Third Quarter 2019 Financial Results
November 7, 2019
Neovasc to Participate in Stifel 2019 Healthcare Conference and Cannacord Genuity 13th Annual MedTech & Diagnostics Forum
November 6, 2019
Neovasc to Provide Update on TF/TS Tiara Program at PCR Valves 2019
November 5, 2019
Neovasc to Submit Full PMA Application for Neovasc Reducer(TM) in 2019
November 1, 2019
Neovasc to Participate in the 28th Annual Credit Suisse Healthcare Conference on Wednesday, November 13, 2019
October 30, 2019
Neovasc to Announce Third Quarter 2019 Financial Results on Thursday, November 7, 2019
October 25, 2019
Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Sponsored Session at the 40th Annual National Congress of the Italian Society of Interventional Cardiology
October 22, 2019
Neovasc Retains Westwicke, ICR for Integrated Communications Counsel
October 16, 2019
Neovasc Announces Notice of US Patent Granted for Tiara(TM) Transcatheter Device for Treatment of Severe Mitral Regurgitation
October 15, 2019
Neovasc's Tiara(TM) for Treatment of Mitral Regurgitation and Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference
September 30, 2019
Tiara(TM) for Treatment of Mitral Regurgitation and Neovasc Reducer(TM) for Treatment of Refractory Angina to be Featured at TCT 2019 Conference
September 23, 2019
Neovasc Announces Changes to its Board of Directors
September 16, 2019
Neovasc to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 4, 2019
The European Society of Cardiology Includes Neovasc Reducer(TM) for the Treatment of Refractory Angina in the European Practice Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes
September 3, 2019
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
August 22, 2019
Neovasc Announces Second Quarter 2019 Financial Results
August 7, 2019
Neovasc to Attend Canaccord Genuity 39th Annual Growth Conference
August 5, 2019
Neovasc to Announce Second Quarter 2019 Financial Results on Wednesday, August 7th
August 2, 2019
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency
July 17, 2019
Neovasc Provides Further Update on Reducer(TM) Program for Treatment of Refractory Angina
July 16, 2019
Neovasc Participates in Round-Robin Study Evaluating In-Vitro Pulsatile Flow Testing of Prosthetic Heart Valves
July 15, 2019
Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA
July 12, 2019
Neovasc Announces Effective Date of Share Consolidation
June 28, 2019
Neovasc Announces Presentations on Tiara(TM) for Treatment of Mitral Regurgitation and Reducer(TM) for Treatment of Refractory Angina at the CSI Frankfurt 2019 Conference
June 27, 2019
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule
June 25, 2019
Tiara(TM) Featured in Presentation at 11th Annual TVT 2019
June 17, 2019
Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million
June 7, 2019
New Tiara and Reducer Data Presented in Several Presentations at the EuroPCR 2019 Conference in Paris
May 23, 2019
Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer(TM) in a Peer Reviewed Article in the International Journal of Cardiology
May 22, 2019
Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million
May 15, 2019
Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million
May 14, 2019
/C O R R E C T I O N from Source -- Neovasc Inc./
May 9, 2019
Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer(TM)
May 6, 2019
Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th
May 3, 2019
Neovasc Provides Highlights from Annual Conference of the DGK, the German Society of Cardiology; Symposium Generates Growing Support for Reducer
April 26, 2019
Neovasc Announces Resolution of Last Remaining Active Litigation
April 17, 2019
Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer(TM) Improves Diastolic Function in patients suffering from severe angina
April 17, 2019
Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results
March 21, 2019
Neovasc Wins German Court Appeal; Announces German Court's Decision to Dismiss CardiAQ's Claim to Co-inventorship of a European Patent for Tiara(TM)
March 21, 2019
Reducer Featured in Presentation at American College of Cardiology's Annual Meeting
March 19, 2019
Neovasc Announces Closing of $5 Million Public Offering of Common Shares
March 15, 2019
Neovasc Completes Successful Quality System Surveillance Audit
March 14, 2019
Neovasc to Announce Year Ended December 31, 2018 Financial Results on Thursday, March 21
March 13, 2019